Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Goodbye Gleevec? Sprycel, Tasigna Vie For Front-Line CML Leadership

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS' Sprycel and Novartis' Tasigna perform better on key endpoints than standard of care, Gleevec, in first-line treatment of chronic myeloid leukemia.
Advertisement

Related Content

Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Bristol's Once-daily Sprycel Faces Off Against Novartis' Tasigna After Clearance In First-line Leukemia
Tasigna Beats Sprycel To First-Line CML Punch
Tasigna Beats Sprycel To First-Line CML Punch
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Exelixis Defends Cancer Drug XL184 After Partner BMS Walks Out
Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight
Ipilimumab Boosts Survival, But With Adverse Events That Need Strict Oversight
UK's NICE Says No To Two CML Drugs; Invites Cost-Sharing Schemes
Beyond Gleevec: What's Next For Novartis Oncology?

Topics

Advertisement
UsernamePublicRestriction

Register

PS070854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel